Abstracts tagged "glucocorticoids"

Abstract Number: 1779 • ACR Convergence 2023
A Novel Inhibitory Pathway of Synovial Inflammation Exerted by Glucocorticoids and TNF Inhibitors Through LAG-3 Up-Regulation
Smadar Gertel¹, Victoria Furer¹, Ari Polachek¹ and Ori Elkayam², ¹Tel Aviv Sourasky Medical center, Tel Aviv, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated condition that results in systemic musculoskeletal (MSK) inflammation, including peripheral synovitis, enthesitis and axial involvement. Glucocorticoids (GCs)…
Abstract Number: 2531 • ACR Convergence 2023
Proton Pump Inhibitor Use Is Associated with Impaired Bone Mineral Density but Not Bone Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases Taking Glucocorticoids
Andriko Palmowski¹, Gabriela Schmajuk², Jinoos Yazdany³, Patti Katz⁴, Jing Li⁵, Rachael Stovall⁵, Emma Kersey⁵, Sabrina Mai Nielsen⁶, Robin Christensen⁷, Henning Bliddal⁸, Zhivana Boyadzhieva⁹, Udo Schneider⁹, Tobias Alexander¹⁰, Burkhard Muche¹¹, Sandra Hermann¹¹, Edgar Wiebe¹¹ and Frank Buttgereit¹¹, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²UCSF / SFVA, San Francisco, CA, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴University of California San Francisco, San Rafael, CA, ⁵University of California San Francisco, San Francisco, CA, ⁶The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁷Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ⁸The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, ⁹Charité Universitatsmedizine - Berlin, Berlin, Germany, ¹⁰Charité Universiätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany, ¹¹Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at increased risk of osteoporosis and fragility fractures. For this population, whether proton pump inhibitor…
Abstract Number: 0447 • ACR Convergence 2023
Glucocorticoid Use in Rheumatoid Arthritis Patients Initiating Biological or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (b/tsDMARDs) in Real Life: Data from BIOBADASER
Lucia Otero-Valera¹, Jose María Alvaro-Gracias², Jerusalem Calvo³, Cristina Campos⁴, Alicia Garcia Dorta⁵, Fernando Sánchez-Alonso⁶ and Isabel Castrejon⁷, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Hospital General Universitario Gregorio Marañon, Madrid, Spain, ³Reina Sofia University Hospital, Córdoba, Spain, ⁴Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ⁵Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁶Fundación Española de Reumatología, Madrid, Spain, ⁷Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Glucocorticoids are frequently used as bridging therapy for rheumatoid arthritis (RA) patients starting conventional synthetic DMARDs. Both EULAR and ACR guidelines (1,2), recommend to…
Abstract Number: 1850 • ACR Convergence 2023
Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data
Andriko Palmowski¹, Eric Roberts², Jing Li², Emma Kersey², Rachael Stovall², Frank Buttgereit³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University of California San Francisco, San Francisco, CA, ³Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ⁴University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁵UCSF / SFVA, San Francisco, CA
Background/Purpose: According to recent ACR and EULAR rheumatoid arthritis (RA) guidelines, glucocorticoids (GCs) should only be used for brief periods or not at all. Our…
Abstract Number: 2555 • ACR Convergence 2023
Cluster Analysis Reveals Subgroups in Patients with Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Implication for Long-term Prognosis Prediction
YuFang Ding¹, Qian Wang¹, Xinping Tian², Mengtao Li², xiaofeng Zeng¹ and Jiuliang zhao², ¹Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Serologically active clinically quiescent (SACQ) is a clinical state of systemic lupus erythematosus (SLE) characterized by high levels of serologic markers without clinical activity.…
Abstract Number: 0676 • ACR Convergence 2023
Mepolizumab Can Achieve Glucocorticoid Discontinuation in Eosinophilic Granulomatosis with Polyangiitis Patients Regardless of IgE Levels: A Retrospective Study at a Single Center
Takashi Yamane¹ and Akira Hashiramoto², ¹Kakogawa Central City Hospital, Kakogawa, Japan, ²Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis associated with eosinophil infiltration and Anti-neutrophil cytoplasmic antibody (ANCA) production. Mepolizumab (MPZ), an anti-IL-5 monoclonal…
Abstract Number: 1878 • ACR Convergence 2023
MRI-determined Intramuscular Fat Changes During Oral Glucocorticoid Treatment: Findings from a Feasibility Study
Thurkka Rajeswaran¹, Emma Harris², hannah Mathieson¹, John Biglands³, Paul Stewart¹, Ai Lyn Tan¹ and Sarah Mackie⁴, ¹University of Leeds, Leeds, United Kingdom, ²The Open University, Milton Keynes, United Kingdom, ³NIHR Leeds Biomedical Research Centre and Medical Physics and Engineering , Leeds Teaching Hospitals NHS Trust Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Oral glucocorticoid therapy has many adverse effects including insulin resistance and myopathy. Long-term glucocorticoid therapy causes a "sarcopenic obesity" phenotype of adiposity with muscle…
Abstract Number: 2557 • ACR Convergence 2023
Clinicopathologic Features of Patients with Giant Cell Arteritis and Thoracic Aorta Repair: A Single Center Experience over Two Decades
Mahmut Kaymakci¹, Nicholas Boire¹, Melanie Bois¹, Mohanad Elfishawi¹, Hannah Langenfeld², Andrew Hanson², Cynthia Crowson¹, Matthew Koster¹, Cornelia M. Weyand³ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Patients with giant cell arteritis (GCA) are at increased risk of thoracic aortic aneurysm and dissection. This late complication of the disease is presumed…
Abstract Number: 0683 • ACR Convergence 2023
Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Duvuru Geetha¹, Frank Cortazar², Annette Bruchfeld³, alexandre Karras⁴, Peter Merkel⁵ and David Jayne⁶, ¹Johns Hopkins University, Baltimore, MD, ²New York Nephrology, Watervliet, NY, ³Karolinska Institutet, Stockholm, Sweden, ⁴HEGP - APHP, Paris, France, ⁵University of Pennsylvania, Philadelphia, PA, ⁶University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the Phase 3 ADVOCATE trial comparing avacopan to a prednisone taper, 81% of patients with ANCA-associated vasculitis (AAV) had renal involvement based on…
Abstract Number: 1889 • ACR Convergence 2023
Utility of a Diagnostic Algorithm in the Assessment of Large Vessel Vasculitis
HUGO AVALOS BOGADO¹, GUSTAVO AÑEZ STURCHIO², Ernesto Trallero-Araguas³, Esther Espartal López⁴, sebastián Sandoval Moreno¹, daniela Ulloa Navas⁵ and Juan José De Agustín De Oro², ¹Rheumatology Department Vall d'Hebrón University Hospital, Barcelona, Spain, ²Vall d'Hebron University Hospital, Barcelona, Spain, ³Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁴Vall Hebron University Hospital, Rheumatology Department, Barcelona, Spain, ⁵Rheumatology Department, Vall Hebron University Hospital, Barcelona, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most prevalent type of primary systemic vasculitis among individuals aged 50 and above. Imaging techniques such as ultrasound…
Abstract Number: 2589 • ACR Convergence 2023
Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Systemic Lupus Erythematosus
Emily Zhang¹, Sarah Capponi², Rebecca Scobell³, Gabrielle Alonzi¹, Madeline Hlobik¹, Esra Meidan⁴, Mindy Lo⁴, Olha Halyabar⁵, Melissa Hazen¹, Ezra Cohen⁶, Lauren Henderson¹, Siobhan Case⁷, Margaret Chang¹, Ankana Daga¹, Jonathan Hausmann⁸, Ahmad Bakhsh¹, Liyoung Kim¹, Daniel Ibanez¹, Holly Wobma⁴, Fatma Dedeoglu⁴, Robert Sundel¹, Peter Nigrovic¹, Karen Costenbader⁹, Mary Beth Son⁴ and Joyce Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Hospital of the University of Pennsylvania, New Hope, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA, ⁵Children's Hospital/Boston Medical Center, Newton, MA, ⁶Bmc, Needham, MA, ⁷Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ⁸Boston Children's Hospital / Massachusetts General Hospital, Cambridge, MA, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic glucocorticoid (GC) morbidity is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The pediatric glucocorticoid toxicity index (pGTI) (Brogan et…
Abstract Number: 0705 • ACR Convergence 2023
Sleep Disturbances in Patients with Vasculitis: Results of the Vasculitis Patient-Powered Research Network Sleep Study (SleepVasc)
Misa Tanaka¹, Saverio Stranges¹, Kathy Speechley¹, Osvaldo Espin Garcia¹, Molly Mason², Renee Borchin³, Cristina Burroughs³, Christine Yeung⁴, Indira Gurubhagavatula⁴, Christian Pagnoux⁵, Peter Merkel⁴ and Lillian Barra¹, ¹Western University, London, ON, Canada, ²Vasculitis Patient Powered Research Network, Philadelphia, PA, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Sleep deprivation and sleep disorders can impair health-related quality of life and increase the risk of chronic diseases, such as cardiovascular disease, and mental…
Abstract Number: 1937 • ACR Convergence 2023
Efficacy of Different Treatment Approaches for Cardiac Sarcoidosis
Frank Cai¹, Anisha Paulson¹, Amy Wozniak², Emily Gilbert² and Rochella Ostrowski², ¹Loyola University Medical Center, Oak Park, IL, ²Loyola University Medical Center, Maywood, IL
Background/Purpose: There is currently a lack of a consensus standardized guideline for the treatment of cardiac sarcoidosis (CS) because of its rarity, heterogeneity of disease…
Abstract Number: 2602 • ACR Convergence 2023
Spatially Resolved Cellular Signatures Predict Corticosteroid Treatment Response in Giant Cell Arteritis
Cecilia Ansalone¹, Sam McAllister², Ethan Pickerill³, Lin Zhang³, Annie Peacock², Dominic McGovern⁴, Holly Leslie⁵, Victoria Kellior², Evelyn Qian², David Gemperline³, Aysin Tulunay Virlan², Sylvia Wright⁶, Paul Cauchi⁶, Timothy Beckman⁶, Lisa Hutton⁶, John Cole¹, Isabella Wulur³, Robert Benschop³, Nigel Jamieson⁵, Carl Goodyear¹ and Neil Basu¹, ¹University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow - School of Infection & Immunity, Glasgow, United Kingdom, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Glasgow - School of Medicine, Glasgow, United Kingdom, ⁵University of Glasgow - School of Cancer Sciences, Glasgow, United Kingdom, ⁶NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
Background/Purpose: Corticosteroids (CS) remain the mainstay of giant cell arteritis (GCA) therapy. Between ~30-70% patients relapse following CS taper and are consequently at risk of…
Abstract Number: 0715 • ACR Convergence 2023
Glucocorticoid Toxicity in Patients with IgG4-Related Disease Within the First Year of Treatment
Ana Mora-Rosas, Gabriela Hernandez-Molina, Edwin Ulises Cortez-Domínguez and Eduardo Martin-Nares, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Patients with IgG4-related disease (IgG4-RD) often require long-term glucocorticoid therapy. The prevalence, types, and underlying factors of glucocorticoid toxicity in IgG4-RD patients remain unknown.…

« Previous Page
1
…
4
5
6
7
8
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].